| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$8,395 ) |
| | 2023 | 2020 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 005 | 5 | NIH | 12/13/2022 | -$8,395 |
| | 2023 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 4 | NIH | 11/29/2022 | -$30,409 |
| | 2023 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 004 | 4 | NIH | 12/5/2022 | $30,409 |
|
| Issue Date FY: 2022 ( Subtotal = $30,409 ) |
| | 2022 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 006 | 4 | NIH | 9/27/2022 | -$510 |
| | 2022 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 4 | NIH | 8/19/2022 | $30,634 |
| | 2022 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 002 | 4 | NIH | 8/23/2022 | $30 |
| | 2022 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 004 | 4 | NIH | 9/8/2022 | $255 |
|
| Issue Date FY: 2021 ( Subtotal = -$115,778 ) |
| | 2021 | 2020 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 5 | NIH | 10/22/2020 | -$115,778 |
| | 2021 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 4 | NIH | 10/21/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $525,456 ) |
| | 2020 | 2020 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 5 | NIH | 5/21/2020 | $525,456 |
|
| Issue Date FY: 2019 ( Subtotal = $530,308 ) |
| | 2019 | 2019 | PYLUM BIOSCIENCES, INC. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 001 | 4 | NIH | 6/20/2019 | $530,308 |
|
|
